http://medvision.lv/

Rīga Stradiņš University (RSU) is the leading institution for academic studies and

scientific research in medicine and health care in Latvia, has founded the Nuclear

Medicine Clinic to improve cancer diagnostics by PET/CT technology

SCIENTIFIC

CENTRE

cyclotron

radiopharmaceuticals

PRODUCTION

GMP

DIAGNOSTICS

PET/CT

THE ONLY NEW

GENERATION PET/CT

SCANNER IN LATVIA

OUR OWN

PRODUCTION OF

RADIOPHARMACEUTICALS

CONSTANTLY IMPROVING

EXPERIENCE IN

PERSONALIZED HEALTHCARE

SCIENTIFIC RESEARCH OF

RĪGA STRADIŅŠ UNIVERSITY IN

NUCLEAR MEDICINE

FDG fluorodeoxyglucose • Breast cancer

• Melanoma

• Kidney, Bladder, Testicular cancer

• Uterine, Cervical, Ovarian cancer

• Lymphomas

• Colorectal cancer

• Lung cancer

• etc.

Ga-PSMA• Prostate cancer

RADIOPHARMACEUTICALS

68GA-PSMA?

GETTING READY FOR TOMORROW IN PROSTATE IMAGING!

Ga radioligand produced in generator that provides

imaging of PET with very short half life

PSMA membrane glycoprotein, part that is involved

in metabolism

Ga-PSMA PET/CT non-invasive diagnostic

technique to image prostate cancer with increased

prostate-specific membrane antigen expression

GETTING READY FOR TOMORROW IN PROSTATE IMAGING!

GETTING READY FOR TOMORROW IN PROSTATE IMAGING!

GETTING READY FOR TOMORROW IN PROSTATE IMAGING!

Physiological

Spread of

PSMA

Metastatic

Prostate

Cancer

vs

COMPARISON with CT and MRI

м

Diagnostic efficacy of 68Ga-PSMA PET/CT compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer

68Ga-PSMA-PET proved to be superior to standard

routine imaging in intermediate to high risk prostate

cancer preoperative lymph node staging

MAURER, Tobias, et al The Journal of urology, 2016, 195.5: 1436-1443.

м

COMPARISON with BS

мComparison of bone scintigraphy and 68Ga-PSMA PET/СTfor skeletal staging in prostate cancer

PSMA-PET sensitivity and specificity 98.8–99.0 % and 98.9–100 %

Bone scintigraphy sensitivity and specificity 82.4–86.6 % and 91.6–97.9 %

(p < 0.001)

PYKA, Thomas, et al. European journal of nuclear medicine and molecular imaging, 2016, 43.12: 2114-2121.

м

68GA-PSMA

replaces CT of the small pelvis and abdominal cavity, as well as MRI with better indicators of specificity and sensitivity

GETTING READY FOR TOMORROW IN PROSTATE IMAGING!

PATIENT

CASE 68GA-PSMA

63 y.o. male

Prostate cancer

T2aN0M0

Gleason 7 (3+4)

2013 radical prostatectomy

2015 biochemical recurrence

PSA 0,33 ng/ml 0,99 ng/ml

2015 radiation therapy for prostatic area PSA 0,24 ng/ml

2016 rising PSA – 0,58 ng/ml

2016 PET/CT Ga-PSMA

Patient case

• complex examination of the whole body

• low radial load

• prostate cancer is detected even at PSA ≤ 1.0

level

• primary tumor and foci of metastasis are

visualized much more clearly than with other

diagnostic methods

• reveals the smallest metastases in the bone

• on the basis of the data obtained, an adequate

method of treatment

68GA-PSMA?

GETTING READY FOR TOMORROW IN PROSTATE IMAGING!

Excellent PATIENT CARE!

AFORDABLE price!

NO waiting list!

SAFE and precise!

Highly qualified medical and

technical PERSONNEL

http://rsunuclearmed.com

BEST

STANDARDS

WELCOME TO RSU

NUCLEAR MEDICINE CLINIC!

relatively high costs of

PET/CT lead to important

COST SAVINGS in cases of

prevention of unnecessary

surgery and other expensive

treatment of cancer

68Ga-PSMA / 1 900 €

CONTACTS

RSU NUCLEAR MEDICINE CLINIC

GARDENES STR.13, RIGA, LATVIA

T. +371 27-078-822

info@rsunuclearmed.com

www.rsunuclearmed.com